公开(公告)号：US10196693B2

公开(公告)日：2019-02-05

申请号：US14962864

申请日：2015-12-08

Applicant: MEDIVATION PROSTATE THERAPEUTICS, LLC

Inventor： Amy Christian Peterson ,  Hirdesh Uppal

IPC: A61K31/415 ,  C12Q1/6886 ,  A61K31/337 ,  A61K31/4166 ,  A61K45/06

Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.

公开(公告)号：US20230210778A1

公开(公告)日：2023-07-06

申请号：US17985235

申请日：2022-11-11

Applicant: Astellas Pharma Inc. ,  Medivation Prostate Therapeutics LLC

Inventor： Douglas Alan Lorenz ,  Sanjay Konagurthu ,  Randy J. Wald ,  Jason A. Everett ,  Sheila Matz ,  Yuuki Takaishi ,  Toshiro Sakai ,  Ryousuke Irie ,  Shinsuke Oba ,  Hiroyasu Toyota ,  Koji Nishimura ,  Atsushi Kanbayashi

IPC: A61K9/20 ,  C07D233/86 ,  A61K9/10 ,  A61K31/4166 ,  A61K47/32 ,  A61K47/38 ,  A61K9/16 ,  A61K31/4164

CPC classification number: A61K9/2054 ,  C07D233/86 ,  A61K9/10 ,  A61K31/4166 ,  A61K47/32 ,  A61K47/38 ,  A61K9/16 ,  A61K9/1652 ,  A61K9/2095 ,  A61K31/4164

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

公开(公告)号：US20220056541A1

公开(公告)日：2022-02-24

申请号：US17523235

申请日：2021-11-10

Applicant: Medivation Prostate Therapeutics LLC

Inventor： Amy Christian PETERSON ,  Hirdesh UPPAL

IPC: C12Q1/6886 ,  A61K31/337 ,  A61K31/4166 ,  A61K45/06

Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.

公开(公告)号：US11186876B2

公开(公告)日：2021-11-30

申请号：US16215340

申请日：2018-12-10

Applicant: Medivation Prostate Therapeutics LLC

Inventor： Amy Christian Peterson ,  Hirdesh Uppal

IPC: A61K31/4164 ,  C12Q1/6886 ,  A61K31/337 ,  A61K31/4166 ,  A61K45/06

Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.

公开(公告)号：US20210069166A1

公开(公告)日：2021-03-11

申请号：US16833819

申请日：2020-03-30

Applicant: Medivation Prostate Therapeutics LLC ,  Astellas Pharma Inc.

Inventor： Jacqueline Gibbons ,  Joyce Mordenti ,  Michiel De Vries ,  Walter Krauwinkel ,  Taoufik Ouatas

IPC: A61K31/4439 ,  A61K45/06

Abstract: This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.

公开(公告)号：US20200060976A1

公开(公告)日：2020-02-27

申请号：US16371618

申请日：2019-04-01

Applicant: Astellas Pharma Inc. ,  Medivation Prostate Therapeutics LLC

Inventor： Douglas Alan Lorenz ,  Sanjay Konagurthu ,  Randy J. Wald ,  Jason A. Everett ,  Sheila Matz ,  Yuuki Takaishi ,  Toshiro Sakai ,  Ryousuke Irie ,  Shinsuke Oba ,  Hiroyasu Toyota ,  Koji Nishimura ,  Atsushi Kanbayashi

IPC: A61K9/20 ,  C07D233/86 ,  A61K9/10 ,  A61K31/4166 ,  A61K47/32 ,  A61K47/38 ,  A61K9/16 ,  A61K31/4164

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

公开(公告)号：US20190169697A1

公开(公告)日：2019-06-06

申请号：US16215340

申请日：2018-12-10

Applicant: Medivation Prostate Therapeutics LLC

Inventor： Amy Christian PETERSON ,  Hirdesh UPPAL

IPC: C12Q1/6886 ,  A61K31/337 ,  A61K31/4166 ,  A61K45/06

Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.

公开(公告)号：US10111861B2

公开(公告)日：2018-10-30

申请号：US15373914

申请日：2016-12-09

Applicant: Medivation Prostate Therapeutics LLC ,  The Regents of the University of Colorado, a body corporate

Inventor： Andrew A. Protter ,  Jennifer Richer ,  Dawn Cochrane

IPC: A61K31/4184 ,  A61K31/4166

Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.

公开(公告)号：US20180235935A1

公开(公告)日：2018-08-23

申请号：US15751542

申请日：2016-08-11

Applicant: Medivation Prostate Therapeutics LLC ,  Astellas Pharma Inc.

Inventor： Jacqueline GIBBONS ,  Joyce MORDENTI ,  Michiel DE VRIES ,  Walter KRAUWINKEL

IPC: A61K31/4166 ,  A61P35/00

CPC classification number: A61K31/4166 ,  A61K31/435 ,  A61K31/438 ,  A61K31/496 ,  A61K31/515 ,  A61K31/55 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.